Currently, β-hydroxy-β-methylglutaryl coenzyme A reductase (HMGCR) inhibitors at the highest tolerable dose are strongly recommended to be initiated immediately at diagnosis in all FH adults. The gene discussed is HMGCR; the disease is familial hyperaldosteronism.